Could Indian Scientists Revolutionize Liver Cirrhosis Treatment?
Click to start listening
Synopsis
A team of Indian scientists has made a significant breakthrough in treating liver cirrhosis by targeting lymphatic vessels. This innovative approach could change how chronic liver disease is managed, offering hope for improved patient outcomes and potentially revolutionizing current treatments.
Key Takeaways
- Groundbreaking treatment for liver cirrhosis developed.
- Focus on enhancing lymphatic drainage using VEGF-C.
- Innovative use of nanocarriers for targeted therapy.
- Significant improvements in animal models observed.
- Published findings in JHEP Reports highlight new avenues for treatment.
New Delhi, Aug 1 (NationPress) A group of Indian researchers has unveiled a groundbreaking method to treat liver cirrhosis by focusing on the lymphatic vessels in the liver and intestine that are compromised in cirrhosis cases.
This chronic liver disease can evolve from mild conditions to fibrosis and ultimately to cirrhosis, often characterized by the distortion of blood and lymphatic vessels in both the liver and intestine. Patients suffering from advanced cirrhosis frequently encounter complications such as fluid buildup in the abdomen.
Researchers from the Institute of Liver and Biliary Sciences (ILBS) in New Delhi and the National Institute of Pharmaceutical Education and Research (NIPER) in Guwahati concentrated on enhancing the drainage capability of lymphatic vessels using nanocarriers loaded with a potent protein known as VEGF-C.
“Vascular endothelial growth factor-C (VEGF-C) is a crucial pro-lymphangiogenic factor that stimulates lymphangiogenesis, which is the formation of new lymphatic vessels. It binds to the vascular endothelial growth factor receptor-3 (VEGFR-3), which is vital for the growth and development of these vessels,” the researchers explained.
The team investigated the therapeutic potential of VEGF-C in alleviating gut lymphatic dysfunction and enhancing lymph drainage.
Due to the hydrophilicity, brief half-life, and systemic side effects of VEGF-C, Dr. Subham Banerjee’s team from NIPER Guwahati initially concentrated on developing VEGF-C encapsulated reverse micelle-based nanocarriers, designed to specifically target VEGFR-3 homodimers.
Subsequently, Dr. Savneet Kaur’s ILBS team rigorously tested the VEGF-C nanocarriers in animal models suffering from advanced cirrhosis and portal hypertension.
The innovative molecule was administered orally to ensure proper uptake by gut lymphatic vessels in the animal models. The findings indicated that VEGF-C nanocarriers significantly enhanced mesenteric lymph drainage, leading to a reduction in ascites.
Crucially, this treatment also resulted in decreased portal pressures, improved cytotoxic T-cell immunity in mesenteric lymph nodes, and lowered local and systemic bacterial load.
Published in the JHEP Reports journal, this research is pioneering in demonstrating that therapeutic lymphangiogenesis using VEGF-C represents a promising approach to reconstructing the fragmented lymphatic network and restoring lymphatic function and drainage in advanced cirrhosis.
Point of View
I find this research highlights the remarkable capabilities of Indian scientists in tackling significant health challenges. The focus on innovative solutions for chronic conditions such as liver cirrhosis reflects a commitment to enhancing healthcare. This groundbreaking study not only showcases scientific expertise but also offers hope for countless individuals affected by this condition.
NationPress
30/08/2025
Frequently Asked Questions
What is liver cirrhosis?
Liver cirrhosis is a chronic liver disease characterized by the scarring of liver tissue, which can lead to severe complications.
How does the new treatment work?
The treatment uses VEGF-C encapsulated nanocarriers to improve lymphatic drainage in the liver and intestine, potentially alleviating complications associated with cirrhosis.
Who conducted this research?
The research was conducted by a collaborative team from the Institute of Liver and Biliary Sciences (ILBS) in New Delhi and the National Institute of Pharmaceutical Education and Research (NIPER) in Guwahati.
Where was this research published?
The study was published in the JHEP Reports journal.
What are the implications of this research?
This research could revolutionize the treatment of liver cirrhosis by enhancing lymphatic function and drainage, potentially improving patient outcomes.
